A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer's Disease

The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL628 in individuals diagnosed with early Alzheimer's disease. Assessing these parameters is critical for establishing the clinical profile and metabolic behavior of the investigational product within this specific patient population. 4, 6, 7

This clinical trial involves a total of 41 patients diagnosed with early Alzheimer's disease. The study population includes both male and female participants. Based on the age range codes provided, the subjects fall within specific age categories defined by the study protocol. The sponsor did not provide additional information regarding lifestyle considerations or specific selection methodologies.

This Phase 1 clinical trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of DNL628 in individuals diagnosed with early Alzheimer’s disease. The study methodology involves a systematic sequence of procedures beginning with a screening visit to assess eligibility. Following enrollment, participants will undergo scheduled follow-up visits to monitor clinical responses and physiological parameters. The protocol concludes with an end-of-study visit to finalize data collection. Total participant involvement is determined by the specific dosing regimen and monitoring requirements. Early termination from the study may occur due to predefined clinical criteria or safety concerns.

The assessment of efficacy in this clinical trial for Early Alzheimer's Disease is not specified.